Basilea Pharmaceutica Ltd. Logo
 

News

 
 
Language
Year
Keyword
 
Friday, April 21. 2017
 
  • Initiation of ceftobiprole pivotal phase 3 clinical program under BARDA contract anticipated within the next three to six months
 
more...
 
Thursday, April 06. 2017
 
  • BAL101553 targets tumor cell proliferation, adaptation to low oxygen and vascularization
  • Switch from weekly to daily oral dosing leads to reduced tumor anti-vascular activity while maintaining tumor growth inhibition
  • Combination with the anti-VEGF therapy bevacizumab shows enhanced anti-tumor response
 
more...
 
Monday, February 27. 2017
 
Basel, Switzerland, February 27, 2017 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that its Board of Directors proposes Dr. Nicole Onetto for election as a non-executive member of the Board at its Annual General Meeting of Shareholders to be held on April 27, 2017.
 
more...
 
Monday, February 20. 2017
 
  • Cresemba® launched by Basilea in first European countries and marketed together with Zevtera®/Mabelio®
  • Entered into distribution and license agreements covering more than 40 countries for both Cresemba and Zevtera/Mabelio
  • Product sales of CHF 7.1 million in Europe and CHF 7.3 million royalties received on 2016 Cresemba US sales
  • CHF 289 million cash and financial investments at year-end
  • Initiation of ceftobiprole clinical phase 3 development program under BARDA agreement anticipated mid-2017 to support potential future US regulatory filing
 
more...
 
Thursday, December 29. 2016
 
Basel, Switzerland, December 29, 2016 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced that, as of January 1, 2017, Ursula Eberhardt will take the role of Head of Global Human Resources and join the Extended Management Committee which reports to the Chief Executive Officer. Ms. Eberhardt succeeds Heidi McDaid, who retires as of December 31, 2016. Ms. Eberhardt has served in various positions in Basilea's Corporate Department and Human Resources team since joining Basilea in 2006 and most recently was deputy Head of Global Human Resources.
 
more...
 
Friday, December 02. 2016
 
Basel, Switzerland, December 02, 2016 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today the expansion of its ongoing oncology drug candidate BAL101553 clinical phase 1/2a oral formulation study. The first patient has been dosed in an additional arm containing adult patients with recurrent or progressive glioblastoma (brain cancer) after prior radiotherapy with or without chemotherapy.
 
more...
 
Tuesday, November 15. 2016
 
Basel, Switzerland, November 15, 2016 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announces that it has launched its antifungal Cresemba® (isavuconazole) in France and that it has sponsored a symposium on current challenges and recent opportunities in the treatment of invasive mold infections. The event was held on November 10, 2016 in Paris, France, and was co-chaired by Professor Élie Azoulay, Medical Intensive Care, Saint-Louis Teaching Hospital, Paris; Professor Jean-Pierre Gangneux, Laboratory of Parasitology and Mycology, University Hospital Rennes, and Professor Olivier Lortholary, Department of Infectious Diseases, Necker - Enfants Malades Hospital, Paris.
 
more...
 
Tuesday, September 20. 2016
 
Basel, Switzerland, September 20, 2016 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that Basilea Pharmaceutica International Ltd. (Basilea) has entered into a license and distribution agreement with Unimedic Pharma AB (Unimedic) for Basilea's antifungal CRESEMBA® (isavuconazole) and antibiotic Zevtera® (ceftobiprole) in the Nordic countries, including Sweden, Denmark and Norway, and Finland.
 
more...
 
Thursday, September 15. 2016
 
  • Basilea grants Asahi Kasei Pharma exclusive license to develop and commercialize isavuconazole in Japan
  • Basilea eligible for upfront and milestone payments of up to CHF 67 million and double-digit royalties

 
more...
 
Tuesday, September 13. 2016
 
Basel, Switzerland, September 13, 2016 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that Basilea Pharmaceutica International Ltd. (Basilea) has entered into a supply, distribution and license agreement with Grupo Biotoscana S.L., (GBT) for Basilea's antifungal CRESEMBA® (isavuconazole) and antibiotic Zevtera® (ceftobiprole) in 19 countries in Latin America including Brazil, Mexico, Argentina and Colombia.
 
more...
 
more
Info